Cargando…
Plasmacytoid Dendritic Cell, Slan(+)-Monocyte and Natural Killer Cell Counts Function as Blood Cell-Based Biomarkers for Predicting Responses to Immune Checkpoint Inhibitor Monotherapy in Non-Small Cell Lung Cancer Patients
SIMPLE SUMMARY: The advent of therapy with immune checkpoint inhibitors (ICIs) has determined a significant survival benefit in patients with non-small cell lung cancer (NSCLC). However, 50–80% of patients do not respond to ICI monotherapy. Therefore, the identification of biomarkers for predicting...
Autores principales: | Pettinella, Francesca, Lattanzi, Chiara, Donini, Marta, Caveggion, Elena, Marini, Olivia, Iannoto, Giulia, Costa, Sara, Zenaro, Elena, Fortunato, Tiago Moderno, Gasperini, Sara, Giani, Matteo, Belluomini, Lorenzo, Sposito, Marco, Insolda, Jessica, Scaglione, Ilaria Mariangela, Milella, Michele, Adamo, Annalisa, Poffe, Ornella, Bronte, Vincenzo, Dusi, Stefano, Cassatella, Marco A., Ugel, Stefano, Pilotto, Sara, Scapini, Patrizia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647811/ https://www.ncbi.nlm.nih.gov/pubmed/37958458 http://dx.doi.org/10.3390/cancers15215285 |
Ejemplares similares
-
Neutrophils inhibit γδ T cell functions in the imiquimod-induced mouse model of psoriasis
por: Costa, Sara, et al.
Publicado: (2022) -
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients
por: Adamo, Annalisa, et al.
Publicado: (2023) -
Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody–Drug Conjugates
por: Belluomini, Lorenzo, et al.
Publicado: (2023) -
The slan antigen identifies the prototypical non-classical CD16(+)-monocytes in human blood
por: Tamassia, Nicola, et al.
Publicado: (2023) -
slanDCs in carcinoma-draining lymph nodes
por: Vermi, William, et al.
Publicado: (2014)